Due to its role in the direct mediation of fatty acid oxidation via acetyl-CoA carboxylase 2 (ACC2), there has been intensive development of small molecule AMPK activators for the treatment of metabolic diseases, such as diabetes and non-alcoholic fatty liver disease. The gene discussed is ACACB; the disease is metabolic dysfunction-associated steatotic liver disease.